New Approaches to Brain Tumor Therapy Consortium

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, New Approaches to Brain Tumor Therapy Consortium sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

New Approaches to Brain Tumor Therapy Consortium: 10 sponsored US clinical trials, none currently recruiting.

New Approaches to Brain Tumor Therapy Consortium sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain and Central Nervous System Tumors, with 2 trials.

Top-decile sponsor footprint

New Approaches to Brain Tumor Therapy Consortium ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00045539
COMPLETED Phase 2

Carmustine Implants in Treating Patients With Brain Metastases

NCT00003878
COMPLETED Phase 1

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00012038
COMPLETED Phase 1

Immunotoxin Therapy in Treating Patients With Malignant Glioma

NCT00006268
COMPLETED Phase 1

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

NCT00006093
COMPLETED Phase 1

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00005855
COMPLETED Phase 1

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00004147
COMPLETED Phase 1

Procarbazine in Treating Patients With Recurrent Brain Tumor

NCT00004004
COMPLETED Phase 2

Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors

NCT00003574
COMPLETED Phase 1

Irinotecan in Treating Patients With Recurrent Malignant Glioma

NCT00003301

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3

Therapeutic Areas

Brain and Central Nervous System Tumors 2

How the New Approaches to Brain Tumor Therapy Consortium early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Brain and Central Nervous System Tumors (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

New Approaches to Brain Tumor Therapy Consortium: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

New Approaches to Brain Tumor Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share New Approaches to Brain Tumor Therapy ConsortiumAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
New Approaches to Brain Tumor Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

New Approaches to Brain Tumor Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this New Approaches to Brain Tumor Therapy Consortium page

10 registered trials is a research-attention snapshot, not an endorsement of New Approaches to Brain Tumor Therapy Consortium or any single study.

  • None of New Approaches to Brain Tumor Therapy Consortium's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Brain and Central Nervous System Tumors is the condition New Approaches to Brain Tumor Therapy Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain and Central Nervous System Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

New Approaches to Brain Tumor Therapy Consortium pipeline card: 10 registered trials from official public datasets.Report a data error.